Treatment of non-Hodgkin's lymphoma with high-dose therapy and hematopoietic stem cell support.
Standard therapies for advanced low-grade lymphomas are not likely to provide a cure, prompting the use of more aggressive approaches. Patients with low-grade lymphoma who receive high-dose therapy with stem cell support appear to have a prolonged disease-free survival, although the benefit to overall survival remains unproven. Patients with chemotherapy-sensitive intermediate- or high-grade relapsed disease have improved survival with high-dose therapy, and those with high-risk disease may benefit from early consolidation while in first remission. Significant questions remain in terms of the proper timing of high-dose therapy, appropriate stratification by risk factors, the value of purging, the role of radiotherapy after transplantation, and the most appropriate source of stem cells for transplantation.
Rizzieri
D A
DA
Duke University Medical Center, Durham, NC 27710, USA.
Chao
N J
NJ
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016465:Bone Marrow Purging; D004305:Dose-Response Relationship, Drug; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008224:Lymphoma, Follicular / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000628:therapy*; D012307:Risk Factors; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents